CURX - Curanex Pharmaceuticals • Financials

Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
12/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2023	0	-0	-	0%	L	-0	L	-0	-	-0	0	0	-0	0	0	-	-
12/2024	0	-0	-	0%	L	1	L	-0	-	-1	0	1	-1	0	0	-	-
12/2025	0	-4	-	0%	L	11	L	-5	-	-10	0	15	-10	0	0	-	-

To see all financials—including updated, you must be Premium.